Kimball Electronics, Inc. First Quarter Fiscal Year 2027 Financial Results - KIMBALL ELECTRONICS INC

Financial Performance:

• Net sales reached $391 million in Q1 FY27, representing a 7% year-over-year increase and 5% sequential growth.
• Organic sales grew 3%, with an additional $12.4 million contributed by the Helvet acquisition; foreign exchange provided a 1% favorable impact.
• Gross margin rate was 7.9%, flat year-over-year, though pressured by higher material costs and Indianapolis facility ramp-up; expected to improve as production scales.
• Adjusted EBITDA totaled $27.6 million (vs. $26.7 million prior year), while adjusted operating income was $17 million (4.3% margin, down from 4.8% prior year).
• Adjusted net income was $6.1 million ($0.25/share), down from $12.3 million ($0.49/share), primarily driven by a temporarily elevated effective tax rate of 66.1% due to cash repatriation taxes.
• Cash and cash equivalents stood at $72.8 million; operating cash flow usage was $19.3 million due to inventory buildup supporting growth.
• Inventory increased to $312.1 million (approx. $40M higher YoY) to support future demand, while PDSOH (Days Sales of Inventory) remained at 88 days.
• Borrowings increased to $235.7 million due to the acquisition; total liquidity (cash + unused credit facilities) was $270.8 million.
• Share repurchases totaled $3.1 million in the quarter; cumulative buybacks since Oct 2015 amount to $118.6 million.

Guidance and Future Outlook:

• Fiscal 2027 sales guidance reiterated at the high end of the range: $1.535 billion to $1.560 billion.
• Full-year adjusted operating income margin guidance maintained between 4.4% and 4.7%.
• Full-year capital expenditure guidance remains $50 million to $60 million.
• Management expects the effective tax rate for the full year to return to the low 30s, excluding one-time withholding tax impacts.
• Future growth is expected to be driven primarily by the medical segment, with double-digit growth anticipated in the coming quarters.
• Production at the new Indianapolis CDMO facility is scheduled to commence in December 2026.

Business Segments and Product Lines:

• Automotive: Generated $171 million (44% of total), up 4% YoY; growth driven by steering components and a new program ramp in Poland.
• Medical: Generated $116 million (29% of total), up 14% YoY; driven by 9% organic growth across drug delivery, respiratory, patient monitoring, surgical instruments, and imaging.
• Industrial: Generated $105 million (27% of total), up 5% YoY; organic growth included strength in off-highway, factory automation, public safety, and smart metering.
• Climate Control: Sales declined due to lower HVAC demand in North America, though new opportunities in high-level assemblies are being pursued.
• Acquisition Integration: Helvet is fully integrated; synergies are being pursued through expanded BD efforts and AI-driven data mining to identify opportunities across the combined footprint.

Market and Competitive Landscape:

• Strong demand in North America for medical devices and automotive steering is contrasting with sluggish EV demand in the North American climate control sector.
• The company is seeing increased customer interest in its combined medical CDMO platform, leveraging capabilities across Tilburg, Pune, and Indianapolis.
• Component supply chain tightness (memory, electronics) is affecting automotive and industrial segments (PCBA focus), whereas the medical segment (full assembly/molding) faces less severe component inflation but some general inflationary pressure.
• A potential company rebranding to "Kimball Solutions" is proposed for shareholder approval to reflect expanded capabilities beyond traditional EMS.

Risks and Challenges:

• Supply chain constraints regarding electronic components and memory are creating cost pressures and potential lead time issues in non-assembly-heavy segments.
• The Indianapolis facility ramp-up is currently weighing on gross margins due to investment costs; full margin recovery depends on production volume increases.
• A significant portion of Q1 EPS variance was due to an artificially low tax rate in Q1 FY26 (Big Beautiful Bill benefits) and a one-time withholding tax impact from cash repatriation.
• Automotive and industrial margins may remain under pressure if inflationary trends on raw materials continue to outpace revenue growth.

Management Commentary and Tone:

• Management expressed strong confidence and optimism regarding the first quarter and the strategic fit of the Helvet acquisition.
• The tone indicates a focus on top-line growth and synergies, with specific mention of "excitement" for the medical CDMO platform's growth potential.
• Leadership emphasized the strategic decision to repatriate cash for acquisition funding as a priority to balance balance sheet support and future growth capex.
• Executives highlighted the talent and passion of the combined team as a key driver of future success.

Analyst Questions and Answers:

• On Helvet Excitement: Management cited improved understanding of partner talent, rising customer interest, and immediate synergy opportunities as reasons for increased excitement.
• On Supply Chain/Margins: Janet clarified that while memory and components are tight, the medical segment is less affected than PCBA-focused areas; inventory build is primarily due to growth trajectory rather than component inflation.
• On Tax Rate: Management explained the 66.1% Q1 rate was due to $30M cash repatriation withholding taxes and contrasted it with an unusually low rate last year; full-year rate expected in low 30s.
• On Capacity Fill Rate: Regarding the Indianapolis facility, management noted immediate production via existing asset transfers, but emphasized that ramping new programs takes time; momentum is strong with facility tours and revenue synergy discussions.
• On Open Orders: A 16% YoY increase to $690 million was attributed to broad-based growth across all geographies and programs, not tied to a single customer, with medical growth expected to accelerate to double digits.

Other Key Points:

• The company's strategic focus remains on balancing the portfolio by growing the high-margin medical segment while maintaining stability in automotive and industrial.
• The annual shareholder meeting is scheduled for next week in Indianapolis, featuring a vote on the company rebrand.
• Business development efforts have been expanded, specifically empowering the Helvet leadership team with new tools to identify real-time market opportunities.